SCHEMBL1177213

SCHEMBL1177213

O=C(CCl)NC(CO)Cc1ccc(Br)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.46
HTT P42858 3/20 0.44
ALDH1A1 P00352 1/20 0.44
NCOA1 Q15788 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
NCOA3 Q9Y6Q9 1/20 0.44
CYP3A4 P08684 1/20 0.43
MAPK1 P28482 1/20 0.43
ROCK2 O75116 1/20 0.41
PRKACA P17612 1/20 0.41
RPS6KB1 P23443 1/20 0.41
IRAK1 P51617 1/20 0.41
PRKX P51817 1/20 0.41
LIMK1 P53667 1/20 0.41
PRKG2 Q13237 1/20 0.41
ROCK1 Q13464 1/20 0.41
PRKG1 Q13976 1/20 0.41
PKN2 Q16513 1/20 0.41
HIPK4 Q8NE63 1/20 0.41
AURKB Q96GD4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18577119 0.86 ROCK2 (0.54) LMNAHTTALDH1A1NCOA1SMN1; SMN2
SCHEMBL1177475 0.86 ROCK2 (0.54) LMNAHTTALDH1A1NCOA1SMN1; SMN2
SCHEMBL1177696 0.84 ALDH1A1 (0.62) HTTALDH1A1NCOA1SMN1; SMN2NCOA3
SCHEMBL1177149 0.82 HTT (0.43) HTTALDH1A1NCOA1SMN1; SMN2NCOA3
SCHEMBL27677329 0.82 MAPK1 (0.50) LMNACYP3A4MAPK1ROCK2PRKACA
SCHEMBL2379241 0.82 MAPK1 (0.50) LMNACYP3A4MAPK1ROCK2PRKACA
SCHEMBL4774975 0.81 LDHA (0.50) HTTALDH1A1SMN1; SMN2CYP3A4MAPK1
SCHEMBL16766937 0.81 LDHA (0.50) HTTALDH1A1SMN1; SMN2CYP3A4MAPK1
SCHEMBL29197625 0.81 LDHA (0.50) HTTALDH1A1SMN1; SMN2CYP3A4MAPK1
SCHEMBL22903496 0.79 CYP3A4 (0.55) LMNACYP3A4MAPK1ROCK2PRKACA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1881827-B1 FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2011-09-28 EP disclosed
US-7888344-B2 Fused thiazole derivatives as kinase inhibitors UCB PHARMA S.A. (BE) 2011-02-15 US disclosed
US-20080306060-A1 Fused Thiazole Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2008-12-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306060-A1 Fused Thiazole Derivatives as Kinase Inhibitors MAP4K2, PDPK1, DAPK2 LMNA 4319/4885HTT 1259/4885ALDH1A1 1901/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.